This two day meeting will focus on regulatory issues in TB drug development and will include topics such as:
Update of the Global TB Drug Development Portfolio
Key Issues in the Critical Path to TB Drug Registration
Biomarkers for TB Drug Development
Design and Challenges for Pivotal Trials
Developing Regimens Containing Multiple Novel Agents
Challenges in TB Drug Development for Special Populations - HIV/TB coinfection, MDR-TB, pediatric TB
Conducting Registration Trials in High Burden Countries - Forging collaborations and building infrastructure
Issues in TB Drug Pharmacovigilance
Lessons learned from HIV drug development
The event is organised by the Bill and Melinda Gates Foundation, the Global Alliance for TB Drug Development (TB Alliance), Treatment Action Group (TAG), and The Stop TB Partnership Working Group on New Drugs.
For questions about the event, please email Heather Ignatius
Related EPHA articles
An extra grant for the TB Alliance to fight against tuberculosis
World TB Day 2006: a mixed picture
Second Global Plan brings the fight against TB to a new level
